BLUEBIRD BIO INC's ticker is BLUE and the CUSIP is 09609G100. A total of 249 filers reported holding BLUEBIRD BIO INC in Q3 2017. The put-call ratio across all filers is 0.94 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $273 | -13.9% | 277,771 | +21.0% | 0.02% | -24.0% |
| Q4 2023 | $317 | -99.9% | 229,542 | +226.4% | 0.02% | 0.0% |
| Q2 2022 | $291,000 | -4.9% | 70,320 | +634.6% | 0.02% | -16.7% |
| Q2 2021 | $306,000 | -65.7% | 9,572 | -53.5% | 0.03% | -68.8% |
| Q4 2020 | $891,000 | +84.5% | 20,599 | +291.4% | 0.10% | +152.6% |
| Q3 2019 | $483,000 | +86.5% | 5,263 | +158.9% | 0.04% | +153.3% |
| Q2 2019 | $259,000 | -24.9% | 2,033 | -7.4% | 0.02% | -25.0% |
| Q1 2019 | $345,000 | +6.2% | 2,196 | -32.9% | 0.02% | +11.1% |
| Q4 2018 | $325,000 | -46.5% | 3,273 | -15.5% | 0.02% | -33.3% |
| Q2 2018 | $608,000 | +29.4% | 3,872 | +40.6% | 0.03% | +8.0% |
| Q1 2018 | $470,000 | +20.2% | 2,753 | +25.3% | 0.02% | +19.0% |
| Q4 2017 | $391,000 | -70.8% | 2,198 | -77.4% | 0.02% | -68.2% |
| Q3 2017 | $1,338,000 | – | 9,742 | – | 0.07% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARMISTICE CAPITAL, LLC | 1,964,000 | $59,215,000 | 1.36% |
| Birchview Capital, LP | 75,500 | $2,276,000 | 1.35% |
| Camber Capital Management LP | 1,000,000 | $30,150,000 | 1.04% |
| Sessa Capital IM, L.P. | 875,000 | $26,381,000 | 1.02% |
| Bain Capital Life Sciences Investors, LLC | 538,179 | $16,226,000 | 0.92% |
| Tarsadia Capital, LLC | 100,000 | $3,015,000 | 0.81% |
| Bullseye Asset Management LLC | 67,872 | $2,046,000 | 0.76% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,304,246 | $39,323,000 | 0.58% |
| MANGROVE PARTNERS IM, LLC | 175,178 | $5,282,000 | 0.53% |
| Parametrica Management Ltd | 37,712 | $1,080,000 | 0.52% |